Geode Capital Management LLC Acquires 50,194 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)

Geode Capital Management LLC raised its holdings in Leap Therapeutics, Inc. (NASDAQ:LPTX) by 18.0% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 329,291 shares of the company’s stock after purchasing an additional 50,194 shares during the quarter. Geode Capital Management LLC’s holdings in Leap Therapeutics were worth $847,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently made changes to their positions in LPTX. Simplify Asset Management Inc. lifted its holdings in Leap Therapeutics by 67.9% during the 2nd quarter. Simplify Asset Management Inc. now owns 631,269 shares of the company’s stock valued at $1,237,000 after purchasing an additional 255,293 shares during the last quarter. Marshall Wace LLP raised its position in shares of Leap Therapeutics by 268.2% in the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock valued at $156,000 after purchasing an additional 58,094 shares during the period. Key Client Fiduciary Advisors LLC lifted its stake in shares of Leap Therapeutics by 13.0% during the 3rd quarter. Key Client Fiduciary Advisors LLC now owns 321,923 shares of the company’s stock worth $827,000 after buying an additional 37,067 shares during the last quarter. Valence8 US LP bought a new stake in shares of Leap Therapeutics during the 3rd quarter worth about $48,000. Finally, HighTower Advisors LLC acquired a new position in Leap Therapeutics in the 3rd quarter valued at about $65,000. 30.46% of the stock is owned by institutional investors and hedge funds.

Leap Therapeutics Stock Down 9.5 %

Shares of Leap Therapeutics stock opened at $3.06 on Friday. Leap Therapeutics, Inc. has a twelve month low of $1.68 and a twelve month high of $4.79. The company has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $2.71. The stock has a market capitalization of $117.25 million, a price-to-earnings ratio of -1.59 and a beta of 0.17.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $5.50 price objective on shares of Leap Therapeutics in a research report on Friday, November 15th.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.